Associated Papers
An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L et al.
Scientific Reports, 2022
35978072 (PubMed )
Supplement: 41598_2022_17791_MOESM3_ESM.xlsx › table
Genomic Landscape of RTK/RAS Pathway and Tumor Immune Infiltration as Prognostic Indicator of Lung Adenocarcinoma.
Yin XQ et al.
Frontiers in Oncology, 2022
35936718 (PubMed )
Supplement: Table_4.xlsx › MAF_infomation
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
Malapelle U et al.
Lung Cancer (amsterdam, Netherlands), 2017
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.
Lai Z et al.
Nucleic Acids Research, 2016
27060149 (PubMed )
Supplement: gkw227_Supplementary_Data.zip › nar-03544-met-k-2015-File003.xls › Suppl._Table_3
Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.
Toledo RA et al.
Endocrine-related Cancer, 2015
25425582 (PubMed )
Supplement: supp_ERC-14-0491_Supplementary_table_2.xlsx › Sheet1
Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.
Sosonkina N et al.
Genes & Genomics, 2014
Select a paper to view details